Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, announced today that Christian Itin, President & Chief Executive Officer of Micromet, Inc. will give a corporate presentation to the investment community at the Rodman & Renshaw 8th Annual Healthcare Conference on Wednesday, November 8th, 2006 at 02:50 p.m. Eastern time (20:50 p.m. Central European Time) at the New York Palace Hotel in New York City.
The company presentation will be webcast live on November 8th and will be accessible through Micromet's website at http://www.micromet-inc.com. A replay and a download of the presentation will also be available via the website.
About Micromet, Inc. (www.micromet-inc.com)
Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Two Phase 2 clinical trials for the treatment of patients with breast cancer and prostate cancer have been completed in Q3, 2006, with adecatumumab (MT201), a recombinant human monoclonal antibody. MT103 (MEDI-538), a BiTE® product candidate, is being studied in a Phase 1 clinical trial for the treatment of patients with Non Hodgkin Lymphoma. Micromet has established a drug development platform based on its BiTE® technology, a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Micromet has established collaborations with MedImmune, Inc. and Serono.
Micromet, Inc. Investors: Ines-Regina Buth +1 760-494-4235 (US) +49 (0)89 895277 221 (Europe) email@example.com Media Europe: Evelyn Wolf +49 (0)89 895277 220 firstname.lastname@example.org Media US: Susan Noonan (212) 966-3650 email@example.com
Copyright © Hugin ASA 2006. All rights reserved.